Eko develops AI-powered digital tools to detect and monitor heart and lung disease
Eko is a digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its suite of AI-powered digital tools. Its FDA-cleared technology is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect disease earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.Eko exists to ensure all patients have access to early heart and lung disease detection that improves and extends their lives.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 20, 2022 | Grant | $2.70M | 1 | National Institutes of Health (NIH) | — | Detail |
Mar 22, 2022 | Series C | $30M | 2 | Morningside Venture Investments PROOF Fund | — | Detail |
Nov 9, 2020 | Series C | $65M | 8 | Highland Capital Partners Questa Capital Management | — | Detail |
Jul 22, 2020 | Grant | $2.70M | 1 | National Institutes of Health | — | Detail |
Sep 25, 2019 | Series B | $20M | 7 | Artis Ventures (AV) | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health (NIH) | Yes | Grant |
Morningside Venture Investments | Yes | Series C |
PROOF Fund | Yes | Series C |
Highland Capital Partners | Yes | Series C |
Questa Capital Management | Yes | Series C |
National Institutes of Health | Yes | Grant |
3M New Ventures | — | Series C |
Artis Ventures (AV) | — | Series C |
DigiTx Partners | — | Series C |
Longevity Vision Fund | — | Series C |